重组人生长激素研究纳入148名35岁以上女性：每日4.5国际单位连用5天、《科学报告》11月12日刊出
《科学报告》2026年11月12日刊出一项研究，考察在促性腺激素释放激素激动剂长方案促排卵中加用重组人生长激素，对35岁以上不同卵巢反应女性的体外受精与胚胎移植结局有何影响。研究共纳入148名年龄在35岁及以上的女性，均接受该长方案控制性卵巢过度刺激。论文数字对象标识为10.1038/s41598-026-64818-9。
生长激素组自促性腺激素启动日起每日注射4.5国际单位重组生长激素，共5天。研究按获卵数划分亚组，获卵不少于4枚为卵巢正常反应组，少于4枚为卵巢低反应组，并按35至37岁、38至40岁、41岁及以上三个年龄层分别比较。
期刊摘要报告，在正常反应组中，35至37岁层各项结局差异无统计学意义，38至40岁层生长激素组的双原核受精数与卵裂胚胎数显著高于对照组，41岁及以上层生长激素组的获卵数、成熟卵数与卵裂胚胎数显著高于对照组。在低反应组中，38至40岁层生长激素组的双原核受精数、卵裂胚胎数与优质胚胎率显著高于对照组。各组的临床妊娠率与着床率在生长激素组有所提高，但差异无统计学意义。作者同时指出，38岁以上正常反应组的样本量相对较小，结论仍需更大队列的后续数据支持。
（来源：《科学报告》）
A Growth Hormone Study Enrolls 148 Women Aged 35 and Older: 4.5 International Units Daily for Five Days, Published in Scientific Reports on November 12
A study published in Scientific Reports on November 12, 2026, examined the effect of recombinant human growth hormone during ovulation induction with a GnRH agonist long protocol on IVF-ET outcomes in women aged 35 and older with different ovarian responsiveness. A total of 148 female patients aged 35 and above undergoing controlled ovarian hyperstimulation with the long protocol were selected. The paper carries digital object identifier 10.1038/s41598-026-64818-9. The growth hormone group received a daily injection of 4.5 IU of recombinant growth hormone, initiated from the starting day of gonadotropin and lasting five days. Participants were divided by oocytes retrieved, with at least four classed as normal ovarian response and fewer than four as ovarian hyporesponsiveness, and outcomes were compared within the age bands 35 to 37, 38 to 40, and 41 and above. The journal abstract reported that in the normal response group there was no statistically significant difference at ages 35 to 37, that the number of 2PN fertilizations and cleavage embryos was significantly higher with growth hormone at ages 38 to 40, and that oocytes retrieved, mature oocytes and cleavage embryos were significantly higher with growth hormone at ages 41 and above. In the hyporesponsive group, 2PN fertilizations, cleavage embryos and the high-quality embryo rate were significantly higher with growth hormone at ages 38 to 40. Clinical pregnancy rates and implantation rates were somewhat improved in the growth hormone group across response groups, but without statistical difference. The authors noted the relatively small sample size in the normal-response group aged 38 and above and said larger cohort data are needed for more solid conclusions.
(Source: Scientific)
来源：《科学报告》
发布：GSM·美国（发布链接）
图片来源：图：一名研究人员正用移液器从微型试管中取样。Maggie Bartlett，公共领域，经 Wikimedia Commons。 / Photo: Maggie Bartlett, public domain, via Wikimedia Commons.
GSM Global · 本篇英文版 English edition of this story
